M. Keiserman

952 total citations
14 papers, 681 citations indexed

About

M. Keiserman is a scholar working on Rheumatology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, M. Keiserman has authored 14 papers receiving a total of 681 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Rheumatology, 7 papers in Genetics and 6 papers in Pathology and Forensic Medicine. Recurrent topics in M. Keiserman's work include Rheumatoid Arthritis Research and Therapies (9 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Lymphoma Diagnosis and Treatment (5 papers). M. Keiserman is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (9 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Lymphoma Diagnosis and Treatment (5 papers). M. Keiserman collaborates with scholars based in Brazil, United States and Germany. M. Keiserman's co-authors include R. Aranda, S Songcharoen, S. Nayiager, C. Codding, Maxime Dougados, Michael Schiff, J-C Becker, T. Li, Chia‐Yen Lin and Alberto Berman and has published in prestigious journals such as Annals of the Rheumatic Diseases, Lara D. Veeken and Arthritis Care & Research.

In The Last Decade

M. Keiserman

13 papers receiving 652 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. Keiserman Brazil 6 559 257 225 171 137 14 681
Uta Engling Poulsen Denmark 4 514 0.9× 172 0.7× 167 0.7× 159 0.9× 61 0.4× 5 603
Fedra Irazoque-Palazuelos Mexico 10 464 0.8× 180 0.7× 155 0.7× 115 0.7× 61 0.4× 24 539
E. C. Hsia United States 5 481 0.9× 265 1.0× 140 0.6× 126 0.7× 68 0.5× 34 546
Zhiyu Ge United States 4 465 0.8× 226 0.9× 148 0.7× 134 0.8× 96 0.7× 5 582
Jeffrey Box United States 3 336 0.6× 177 0.7× 137 0.6× 112 0.7× 95 0.7× 5 445
Ayanbola Elegbe United States 8 308 0.6× 142 0.6× 116 0.5× 104 0.6× 59 0.4× 22 424
K. D. Watson United Kingdom 3 519 0.9× 160 0.6× 244 1.1× 126 0.7× 79 0.6× 3 724
George Vratsanos United States 9 519 0.9× 186 0.7× 296 1.3× 123 0.7× 132 1.0× 13 738
Daniel Siri Argentina 4 517 0.9× 253 1.0× 189 0.8× 114 0.7× 72 0.5× 4 645
S Songcharoen United States 6 421 0.8× 184 0.7× 141 0.6× 123 0.7× 69 0.5× 7 654

Countries citing papers authored by M. Keiserman

Since Specialization
Citations

This map shows the geographic impact of M. Keiserman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Keiserman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Keiserman more than expected).

Fields of papers citing papers by M. Keiserman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Keiserman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Keiserman. The network helps show where M. Keiserman may publish in the future.

Co-authorship network of co-authors of M. Keiserman

This figure shows the co-authorship network connecting the top 25 collaborators of M. Keiserman. A scholar is included among the top collaborators of M. Keiserman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Keiserman. M. Keiserman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
2.
3.
4.
5.
6.
Wallace, Daniel J., Kathryn Hobbs, Megan E. B. Clowse, et al.. (2015). Long‐Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate‐to‐ Severe Systemic Lupus Erythematosus: Results From an Open‐Label Extension Study. Arthritis Care & Research. 68(4). 534–543. 33 indexed citations
7.
8.
Genovese, M. C., G. Léon, Eduardo Mysler, et al.. (2012). FRI0193 SC vs IV abatacept in RA: post-hoc efficacy analysis of long-term acquire (SC) data with aim (IV) data. Annals of the Rheumatic Diseases. 71. 378–378. 2 indexed citations
9.
Schiff, Michael, M. Keiserman, C. Codding, et al.. (2011). Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study. Annals of the Rheumatic Diseases. 70(11). 2003–2007. 46 indexed citations
10.
Léon, G., Eduardo Mysler, M. Keiserman, et al.. (2011). Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis & Rheumatism. 63(10). 2854–2864. 155 indexed citations
11.
Soriano, Enrique R., Claudio Galarza-Maldonado, Mario H. Cardiel, et al.. (2008). Use of rituximab for the treatment of rheumatoid arthritis: the Latin American context. Lara D. Veeken. 47(7). 1097–1099. 13 indexed citations
12.
13.
Keiserman, M., et al.. (1999). Fibrose pulmonar na eslerose sistemica progressiva: frequencia e associacoes clinicas. Revista Brasileira de Reumatologia. 39(2). 75–80. 3 indexed citations
14.
Staub, Henrique Luiz, et al.. (1993). Rheumatoid arthritis, transverse myelitis and antiphospholipid antibodies.. PubMed. 10(6). 626–7. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Uta Engling Poulsen Breakdown of academic impact, for papers by Fedra Irazoque-Palazuelos Breakdown of academic impact, for papers by E. C. Hsia Breakdown of academic impact, for papers by Zhiyu Ge Breakdown of academic impact, for papers by Jeffrey Box Breakdown of academic impact, for papers by Ayanbola Elegbe Breakdown of academic impact, for papers by K. D. Watson Breakdown of academic impact, for papers by George Vratsanos Breakdown of academic impact, for papers by Daniel Siri Breakdown of academic impact, for papers by S Songcharoen
Rankless by CCL
2026